Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

on and $0.4 million for the nine months ended September 30, 2007 and 2006, respectively. During the nine months ended June 30, 2007, the Company recognized $0.8 million of interest income associated with its investments and a $2.8 million reduction in non-cash interest expense for the net decrease in the fair value of warrants issued in connection with the February and June 2007 financings.

The foreign exchange loss was $1.3 million for the nine months ended September 30, 2007, compared to $1.7 million for the corresponding period in 2006. The decrease in 2007 was due to a lower inter-company loan balance and more stable spreads between the value of the U.S. dollar and the Euro compared to the prior year as the dollar denominated inter-company loan between the Company's subsidiaries is revalued each quarter based on changes in the value of the dollar versus the Euro, with all related changes recognized in earnings.

Net loss for the nine months ended September 30, 2007 was $15.4 million, compared to a net loss of $17.5 million in the corresponding period in 2006. Basic and diluted net loss per share was $0.78 in the nine months ended September 30, 2007, on 19.7 million weighted average shares outstanding, compared to basic and diluted net loss per share of $1.31 in the nine months ended September 30, 2006, on 13.4 million weighted average shares outstanding.

L-MTP-PE Regulatory Status

The L-MTP-PE New Drug Application (NDA) includes efficacy and safety data from 678 patients with non-metastatic resectable osteosarcoma, 332 of whom received L-MTP-PE, and from 115 patients with metastatic or unresectable osteosarcoma, 39 of whom received L-MTP-PE, in the controlled Phase 3 trial conducted by the Pediatric Oncology Group (POG) and the Children's Cancer Group (CCG), now the Children's Oncology Group (COG), sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute. Also included are safety and efficacy data from 51
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 25, 2014 Background: , ... Recovery (CCAR). He is a pioneer in the field of ... in Connecticut's state treatment system and when he retired, he ... him while in public service. , 1. ... critical decisions concerning them? , 2. Can the recovery ...
(Date:10/25/2014)... 25, 2014 Market Research ... Industry, 2009-2019 is a professional and in-depth ... Diagnostics industry. The report firstly reviews the ... classification, application and manufacturing technology. The report ... of Molecular Diagnostics listing their product specification, ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply to ... reduce the risks associated with the surgery, according to a ... stop the blood supply to the heart to be able ... the heart will reduce its ability to produce energy because ... flow to another large muscle, such as an arm or ...
(Date:10/25/2014)... Researchers who discovered antibiotics in farmed and wild ... The use of antibiotics in animals, including ... to the development of antibiotic-resistant bacteria that threaten ... study. Each year in the United States, ... kill about 23,000, according to the Infectious Diseases ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... is not a luxury;,it is an activity that is ... survey analysis of 30 companies and in-depth interviews,with seven ... in a,difficult economy., The complete study addresses areas ... goals of benchmarking studies, how companies are,demonstrating value through ...
... chemical serotonin influences fat metabolism , , THURSDAY, June 5 ... a frustrating truism familiar to the diet-conscious choosing between ... weight control isn,t just a matter of what you ... system is genetically predisposed to process fat. , The ...
... Forum to Explore Solutions Presented by The Massachusetts ... 5 "We are greatly,concerned in this state about ... of our returning veterans, the stress, depression and ... specter of rising levels of,domestic violence and suicide. ...
... The U. S. Army Corps of,Engineers, in partnership ... and recreation industry partners, will,participate in the first ... On this day, more than 75 organizations will ... privately-managed recreation sites,across the country according to event ...
... and ... more, ... and figure competitors Allison,Frahn and Tina Durkin, will represent GNC at the ... in Atlanta., Chad, part of the World Natural Bodybuilding Federation (WNBF), ...
... top equine veterinarians perform leading-edge techniques and,identify ... lives of both,horses and humans, WASHINGTON, ... Research (FBR) releases its feature film Majestic ... Dr. Larry Bramlage (Rood & Riddle,Equine Hospital) ...
Cached Medicine News:Health News:Demonstrating the Value of Benchmarking in an Uncertain Economy 2Health News:Weight Gain May Not Be Based Just on What You Eat 2Health News:Weight Gain May Not Be Based Just on What You Eat 3Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2Health News:Army Corps of Engineers Will Host National Get Outdoors Day Activities at Six Corps Project Sites 2Health News:Rite Aid Health and Beauty Expo to Showcase GNC Athletes 2Health News:The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere 2
(Date:10/25/2014)... Oct. 24, 2014  Heska Corporation (Nasdaq: ... You to Join Its Third Quarter 2014 Earnings Conference ... a.m. (MDT) / 11:00 a.m. (EDT)Where: , www.heska.com ... on the front page of this website)How:Live over the ... the address above.  Alternatively, you may use the following ...
(Date:10/25/2014)... , Oct. 24, 2014  The National Association ... latest results achieved by Kentucky,s ... The National Precursor Log Exchange (NPLEx) ... point of sale and helps flag meth offenders ... often set up NPLEx "watch lists" that notify ...
(Date:10/25/2014)... 2014   Metanome, Inc. , a ... data analysis, was the genomic sequencing provider for Seres ... clinical trial of SER 109, an Ecobiotic® therapeutic for ... infections (CDI). Metanome has provided genomic ... clinical programs. Such genomic characterization has enabled the study ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Kentucky's NPLEx Technology Making Significant Progress 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2
... 2, 2012  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... Marketing Authorization Application (MAA) with the European Medicines Agency ... weight control, including weight loss and maintenance of weight ... patients who are overweight (BMI >27) and have at ...
... 2012 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... leading specialty hospital management solution provider and operator ... imaging centers in China, today announced it will release ... full year 2011 after the market closes, at ...
Cached Medicine Technology:Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 2Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 3Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 4Concord Medical to Report Fourth Quarter and Full Year 2011 Financial Results on March 21, 2012 2